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Abstract
Background: Elevated serum uric acid levels (SUA) have been associated with an increased risk of cardiovascular 
diseases and the metabolic syndrome (MetS) and are often reported to be higher in females than in males. The aim of 
this report is to determine the prevalence and clinical correlates of hyperuricaemia and also to evaluate associations 
with the MetS in people with type 2 diabetes mellitus (DM).
Methods: This was a cross-sectional study conducted in people with type 2 DM in Lagos, Nigeria. Hyperuricaemia was 
defined by cut-off values of > 7 mg/dl for men and > 6 mg/dl for women. The diagnosis of MetS was made using the 
new definition by the American Heart Association and other related bodies. Clinical and biochemical parameters were 
compared between subjects with hyperuricaemia and normouricaemia. Statistical analysis included usage of Student's 
t test, Pearson correlation coefficients, multivariate regression analysis and chi square.
Results: 601 patients with type 2 DM aged between 34-91 years were recruited for the study. The prevalence rates of 
hyperuricaemia and the MetS were 25% and 60% respectively. The frequency of occurrence of hyperuricaemia was 
comparable in both genders (59% vs 41%, p = 0.3). Although, the prevalence of the MetS in subjects with 
hyperuricaemia and normouricaemia was comparable (61 vs 56%, p = 0.1), a higher proportion of hyperuricaemic 
subjects had 3 or more components of the Mets compared with normouricaemic subjects. Possible predictors of 
hyperuricaemia include central obesity, smoking and elevated serum triglycerides (TG). SUA levels were found to be 
positively and significantly associated with serum TG (r = 0.2, p = 0.0001) and total cholesterol (r = 13, p = 0.001).
Conclusion: The prevalence of hyperuricaemia in subjects with type 2 DM is comparable in both genders and possible 
predictors of hyperuricaemia are potentially modifiable. SUA is positively and significantly associated with serum TG 
and total cholesterol.
Background
Diabetes mellitus is a chronic disorder that is associated
with cardiovascular complications of which the metabolic
syndrome (MetsS) plays a prominent role. The metabolic
syndrome (MetS) is a cluster of cardiovascular risk fac-
tors that is characterized by obesity, central obesity, insu-
lin resistance, atherogenic dyslipidemia, and
hypertension [1]. Hyperuricaemia or elevated serum uric
acid level (SUA) is a biochemical entity that is gaining
increasing importance as it has been found by some
researchers to be not only a cardiovascular risk factor but
also play a role in the development of renal and metabolic
diseases [2-4]. Some reports on SUA and the metabolic
syndrome have noted that increased SUA concentration
is associated with an increased prevalence of some of the
parameters - obesity, dyslipidemia and hypertension -of
the metabolic syndrome [5,6]. In these reports carried
out in non DM subjects the documented prevalence rates
of hyperuricaemia ranged from 13-19% [5,6] with greater
proportions of males having elevated levels of SUA com-
pared to females. Although SUA levels are usually higher
in males than in females, there is however a noted
increase in SUA levels in both sexes with increasing age.
The report by T uomilhto et al showed that SU A levels
were comparable in both sexes in Melanasian Indians [7].
It is not known what the sex distribution of hyperuricae-
mia is, in people with DM from sub-Saharan Africa as
there are only few reports on this subject from the region.
Available reports on hyperuricaemia from sub-Saharan
Africa, [8,9] were carried out in non DM subjects and in
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these studies, hyperuricaemia was found to associated
with increased cardiometabolic risk.
The main objective of this report was to determine the
prevalence of hyperuricaemia and its clinical correlates in
DM. We also set out to determine the prevalence of hype-
r u r i ca e m i a  i n  D M  s u b j ec t s  w i t h  t h e  M e t S  a n d  a l s o  t o
evaluate possible associations of hyperuricaemia with the
MetS. We thus hope to document the scope of the burden
of hyperuricaemia and also describe the phenotype of
CVS risk factors in our subjects with type 2 DM.
Methods
This was a cross sectional study carried over a period of 3
months from November 2008 to January 2009. The study
population consisted of subjects with DM who were
receiving care at the Lagos State University Teaching
Hospital (LASUTH), and General hospital Gbagada.
These are the two largest DM centres in Lagos state, a
cosmopolitan city in the South Western region of Nigeria
and thus the study subjects were deemed to be represen-
tative of subjects with DM from Nigeria. Inclusion crite-
ria included having type 2 DM. DM subjects who were
excluded included those who were on thiazide diuretics
(these drugs cause iatrogenic elevation in SUA), those
who were taking medications for hyperuricaemia, and
pregnant women. Ethical approval was obtained from the
Ethical committee of both hospitals and informed con-
sent was obtained from the study subjects.
Case Report forms were interviewer administered to
the study subjects in order to obtain information on bio-
data, histories pertaining to diabetes mellitus, hyperten-
sion and medications used in managing these conditions.
Histories of smoking and alcohol ingestion were also
obtained. All the study subjects underwent physical
examination which included anthropometric and blood
pressure measurements. The anthropometric measure-
ments comprised of waist circumference, height and
body weight, and the body mass index (BMI) was calcu-
lated as weight/height2 (kg/m2). Waist circumference was
determined by applying a tape measure to the midpoint
between the inferior margin of the last rib and the crest of
the ilium. Blood pressure measurement was done with a
mercury sphygmomanometer.
Laboratory analysis
Fasting venous blood samples were taken for the determi-
nation of four parameters of the lipid profile and these
were total cholesterol (TCHOL), high density lipoprotein
cholesterol (HDL-C), and triglyceride (TG). Total choles-
terol assay was done using a modified method of Lieber-
mann-Burchard [10], HDL-cholesterol by precipitation
method [11] and TG was estimated using a kit employing
enzymatic hydrolysis of TG with lipases [12]. LDL-C was
calculated using the Friedwald's formula [13] LDL =
(TCHOL - HDL-C) - TG/5 when the values of TG were
less than 400 mg%. Plasma glucose was measured using
the glucose oxidase method [14] and SUA was measured
on a standard autoanalyzer.
Lipids, blood glucose and uric acid were analysed spec-
trophotometrically. The name and model of the spectro-
photometer used are SSRFI and BSA 3000.
The intra-assay CVs for SUA, cholesterol, TG and glu-
cose were 2.26%, 2.36%, 3.45% and 1.63% and the inter-
assay CVs were 1.31%, 1.14%, 2.89% and 1.33% respec-
tively.
Diagnostic criteria
1. The presence of the metabolic syndrome was deter-
mined using the new definition [15]. The presence of
three or more of any of the following is a pointer to
the MetS. waist circumference (WC) greater than 102
cm in men and 88 cm in women; serum triglycerides
(TG) level of at least 150 mg/dl (1.69 mmol/L); high-
density lipoprotein cholesterol (HDL-C) level of less
than 40 mg/dl (1.04 mmol/L) in men and 50 mg/dl
(1.29 mmol/L) in women; blood pressure of at least
130/85 mm Hg
2. Hyperuricaemia: This was said to be present with
serum SUA levels of >6 mg/dl in women and >7 mg/dl
in men [16].
Statistical Analysis
Data were analyzed using SPSS version 15. Categorical
variables were analysed using chi-square tests. Indepen-
dent t-test was used to compare continuous variables
among the group with hyperuricaemia and with the nor-
mouricaemic group. Pearson correlation coefficient
determination was performed to evaluate the degree of
association between uric acid and various clinical and
biochemical parameters. Quantitative data are expressed
as mean and standard deviation (SD). P values of < 0.05
were considered to be statistically significant.
Results
The mean age, standard deviation (SD) and age range of
the study subjects were 59.9 (10.3) years and 34-91 years
respectively. The number and proportions of the males to
the females in this report is 268 (44%): 335 (56%). The
mean age of the females was comparable to that of the
males (60.2(9.2) vs 59.6(11.6), p = 0.4). Females differed
largely from the males in that they had statistically signif-
icant higher mean waist circumferences and body mass
indices (94.7 (14.5)cm vs 91.9(14) cm, p = 0.017 and 29.1
(6.4)kg/m2 vs 27.2 (4.9) kg/m2, p = 0.001).
A total number of 325 people had hypertension and
this made up 54% of the study subjects. A higher propor-
tion of females -60%- than males -47%- had hypertension
and this difference was statistically significant, p = 0.002.Ogbera and Azenabor Diabetology & Metabolic Syndrome 2010, 2:24
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The majority -465 (78%) of the subjects were on oral
hypoglycaemic agent, 53(9%) were on insulin treatment
and 77 (13%) were on a combination of oral hypoglycae-
mic agents and insulin. The classes of antihypertensive
agents used were the calcium channel blockers, ACE
inhibitors, ACE receptor antagonists, beta blockers and
alpha blockers. A summary of the clinical and biochemi-
cal parameters of the study subjects is shown in Table 1.
Hyperuricaemia was noted in 150 subjects thus giving
an overall prevalence rate of 25%. The proportion of
female subjects with hyperuricaemia was comparable to
that of the males with hyperuricaemia (59% vs 41%, p =
0.3). There was no age difference between subjects with
hyperuricaemia and normouricaemic subjects (60 (10) vs
59.7 (10), p = 0.7). There was no statistical significant dif-
ference in the distribution of hyperuricaemia between the
different age decades (p = 0.08). The prevalence of hyper-
uricaemia did not have any particular pattern with
increasing age, however, there was a steep increase after
80 years of age and this increase was noted only in
females. The sex and age distribution of the subjects with
hyperuricaemia are shown in Figure 1. The mean levels of
SUA in subjects with hyperuricaeamia and without hype-
ruricaemia were 8.1(2.0) mg% and 4.5 (1.2)mg% respec-
tively. Subjects with hyperuricaemia had significantly
higher mean levels of TG and TCHOL than those with
normouricaemia. A comparison of clinical and biochemi-
cal parameters between subjects with hyperuricaemia
and those with normouricaemia is shown in Table 2. The
overall prevalence of the MetS was 355 (60%) and the
proportion of the subjects with MetS who had hyperuri-
caemia, was comparable to that of the subjects with MetS
who had normouricaemia (92(61%) vs 263 (56%), p = 0.1).
The distribution of the number of the components of the
MetS as depicted in Figure 2 showed that the percentages
of subjects with hyperuricaemia that had 3 or more com-
ponents of the MetS was significantly higher (p = 0.02)
than that of normouricaemic subjects.
A comparison of the distribution of the proportions of
the MetS defining criteria in subjects with and without
hyperuricaemia is shown in Table 3. A higher proportion
of hyperuricaemic subjects had elevated serum TG and
central obesity compared with normouricaemic subjects.
A correlation analysis between SUA levels and some clin-
ical and biochemical parameters showed that there was a
significant and positive association between SUA and
serum TG and total cholesterol. These and other results
are showed in Table 4.
A total number of 229 subjects corresponding to 38% of
the study subjects had a significant alcohol history. More
subjects with hyperuricaemia had a significant alcohol
history than those with normouricaemia but this differ-
ence was not statistically significant (42% vs 37%, p = 0.2).
Significant smoking histories was documented in 159
(27%) of the study subjects. The proportion of subjects
with significant smoking history that had hyperuricaemia
was higher than those who had normouricaemia and this
difference was statistically significant (34% vs 24%, p =
0.01).
The results of a multivariate regression model with
hyperuricaemia as the dependent variable and the com-
ponents of the metabolic syndrome components, age,
gender, duration of diabetes, and life alcohol drinking and
smoking as independent variables are presented in Table
5. Central obesity, smoking and elevated serum TG levels
were found to be possible predictors of the hyperuricae-
mic state.
Discussion
We report the overall prevalence rate of hyperuricemia to
be 25% with comparable proportions of males and
females having elevated SUA. We note in this report that
hyperuricaemic subjects had a comparable mean age with
normouricaemic subjects and that the proportion of sub-
jects with hyperuricaemia did not increase with increas-
ing age except for the females in which the proportions of
females with elevated SUA increased steeply after 80
years of age. The prevalence of the MetS in the study pop-
ulation was 60% and the proportion of the subjects with
the MetS who had hyperuricaemia, was comparable to
that of the subjects with MetS who had normouricaemia
(92(61%) vs 263 (56%), p = 0.1). The clinical and biochem-
ical parameters that differed between the hyperuricaemic
and normouricaemic subjects included, serum TG,
smoking histories and waist circumference measure-
ments. The possible predictors of elevated SUA included
centripetal obesity, elevated serum TG and a positive
smoking history.
SUA acid is a diprotic acid produced by xanthine oxi-
dase from xanthine and hypoxanthine, which in turn are
produced from purine [17]. SUA acid is a strong reducing
agent and in humans, over half the antioxidant capacity of
Table 1: Baseline characteristics of the study sample
Parameter Mean (SD) Range
Age (years) 60 (10.3) 34-91
BMI (kg/m2) 28.3(5.8) 14.8-58.6
WC (cm) 93.5 (14.3) 28.9-191
Duration of DM (years) 7 (6.9) 0.1-38
Uric acid (mg/dl) 5.8 (2.3) 1.5-15Ogbera and Azenabor Diabetology & Metabolic Syndrome 2010, 2:24
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blood plasma comes from SUA [17]. The resultant effects
of elevated SUA include gout, Lesch Nyhan's syndrome,
and uric acid stones [3,18]. The role of hyperuricaemia in
DM has been a subject of much debate as some research-
ers report it to be a resultant effect of DM and others
have reported it to be a risk factor for the development of
type 2 DM [19,20]. Hyperuricaemia has also been found
to be associated with insulin resistance and components
of the MetS [21]. Elevated levels of SUA or hyperuricae-
mia have been reported to be predictors of cardiovascular
diseases in non diabetic patients and those with type 2
diabetes [22,23].
Our results on the prevalence rate of hyperuricaemia
are similar to those obtained from the Melanasian Indi-
Table 2: Comparison of clinical and biochemical parameters between normouricaemic and hyperuricaemic subjects.
Variable Normouricaemic subjects Hyperuricaemic subjects p
Age (years) 60.1(10.5) 59.7(10) 0.09
BMI(kg/m2) 28.2 (5.6) 28.9 (6.4) 0.3
WC (cm) 92.8 (14) 96.1(14.5) 0.05
Duration of DM (years) 6.7(6) 7.2(6.9) 0.2
TCHOL (mg%) 184.2 (46.4) 191.1(43.2) 0.5
TG(mg%) 98.1(45.2) 119.4(59) 0.001
HDL-C(mg%) 45.1(19) 46.8(24.4) 0.6
LDL-C (mg%) 117.1 (48) 119 (63.5) 0.7
FBS (mg%) 157 (75) 160.5 (80.5) 0.6
Figure 1 Sex and age distribution of the subjects with hyperuri-
caemia.
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ans from Fiji [7]. Our findings of comparable proportions
of elevated SUA in both sexes may be attributable to the
age of the females since the majority of them were aged
greater than 50 years and likely to be menopausal. Meno-
pausal women have been shown to have higher SUA lev-
els than pre menopausal women and these changes are
thought to result from changes in metabolism as a conse-
quence of the menopause [24]. Although SUA increases
with aging, this increase may occur more in women espe-
cially after attainment of menopause. In a Chinese study
carried out in old people, hyperuricaemia occurred more
in women than in men and the increase in proportions of
women with hyperuricaemia was noted more in post
menopausal women (22% vs 20%) [25]. SUA increased
Table 3: The distribution of the components of the Mets in subjects with and without the Mets.
Parameter Hyperuricaemic subjects Normouricaemic subjects P
Elevated TG 31(21%) 5 (12%) 0.01
Reduced HDL-C 92 (61%) 261(58%) 0.4
Centripetal obesity 92 (61%) 236 (52%) 0.04
Hypertension 82 (55%) 243(54%) 0.8
Table 4: Pearson's correlation coefficients (r) for uric acid and some clinical and biochemical parameters
Parameter correlation coefficient (r) p
LDL-C 0.02 0.51
TG 0.2 0.0001
HDL-C 0.01 0.8
TCHOL 0.13 0.001
Duration of DM -0.07 0.08
FBS 0.001 0.86
HBa1c 0.1 0.1
BMI 0.05 0.21
WC 0.06 0.1
Syst 0.04 0.5
Diast 0.12 0.08
Age 0.06 0.3Ogbera and Azenabor Diabetology & Metabolic Syndrome 2010, 2:24
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with age in Japanese men and women, irrespective of
body mass index and alcohol consumption [26]. In our
report, the proportions of subjects with hyperuricaemia
did not necessarily increase with age except for in women
aged over 80 years.
We have shown in this report the clinical parameter
that is likely to be contributory to the presence of hyperu-
ricaemia is central obesity. Some researchers have how-
ever shown a possible association between SUA to BMI.
Bonora et al [21] showed a positive association between
SUA and BMI in young men and Wingrove et al [24]
showed BMI to be a predictor of elevated SUA in pre but
not premenopausal women.
Hyperuricaemia is reported in 25-50% of adults with
hypertension [27] and in some other reports [28,29] it
was found to predict the development of hypertension. In
our study, we note that hypertension occurred in 54% of
the study subjects with females being more affected than
men. We also found the proportion of hypertensive and
non hypertensive patients with hyperuricaemia was com-
parable and there was no association between SUA and
blood pressure readings. Lu et al [25] had similar results
to ours and found no correlation between uric acid and
blood pressure readings.
The MetS, a cluster of cardiovascular risk factors which
include obesity, aging, sedentary lifestyle and dyslipidae-
mia is frequently reported in DM [30]. The possible role
of elevated SUA in the MetS is a subject that has become
topical in the past few years with some studies reporting
SUA to be related to the presence of the Mets [4,31]. In
this report, although the presence of the Mets was com-
parable in subjects with hyperuricaemia and those with
normouricaemia, a significantly higher proportion of
subjects with had hypertriglycaeridaemia and central
obesity. In our correlation analysis, TG and total choles-
terol were found to be positively correlated with SUA. We
also found that more components of the MetS were noted
in subjects with hyperuricaemia compared to those with
normouricaemia. High levels of triglycerides and SUA
have each been reported not only to be independently
associated with an elevated risk for coronary heart dis-
ease but also show strong associations between SUA and
triglyceride [5,32].
Significant alcohol ingestion especially beer intake has
been linked with elevated SUA levels and this scenario
has been suggested to be likely due to the high purine
content in beer [33,34]. In this report, significant smok-
ing histories were found more in subjects with hyperuri-
caemia than those with normouricaemia and smoking
was also found to be a possible predictor of hyperuricae-
mia. These reports differed somewhat from those by
Nikanishi et al [34] who found that alcohol ingestion and
smoking were possible determinants of the occurrence of
hyperuricaemia.
Table 5: Predictors of Hyperuricaemia
Variable Odds ratio 95% Confidence interval p
Age 0.9 0.85-1.164 0.96
BMI 0.8 0.63-1.183 0.3
WC 1.9 1.3-2.7 0.006
Sex 1.4 0.78-2.5 0.2
Alcohol history 0.4 0.06-2.8 0.4
Smoking history 0.2 0.06-0.9 0.001
HDL-C 0.9 0.8-1.2 0.4
TG 0.9 0.98-0.99 0.004
Duration of DM 0.6 0.4-0.95 0.2
HbA1c 1.2 0.6-2.21 0.5Ogbera and Azenabor Diabetology & Metabolic Syndrome 2010, 2:24
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Conclusion
Hyperuricaemia is associated with the MetS and its prev-
alence is comparable in both genders and in subjects with
and without hypertension. The possible predictors of
hyperuricaemia include centripetal obesity, significant
smoking history and elevated serum TG.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AOO designed the study, participated in data collation, statistical analysis,
funding and writing the draft of the manuscript. AE participated in the labora-
tory analysis, funding, and data collation. All authors read and approved the
final manuscript.
Acknowledgements
I wish to acknowledge, Dr F Akingabde and Dr A Senbanjo who assisted in the 
administration of the Case Report Forms and Miss Remi Olowo who assisted 
with data collation.
Author Details
1Department of Medicine, Lagos State University Teaching Hospital, Ikeja, 
Lagos, Nigeria, 2Department of Medicine, General Hospital Gbagada, Lagos, 
Nigeria and 3Department of Surgery, Lagos University Teaching Hospital, Idi-
araba, Lagos, Nigeria
References
1. Deedwania PC, Gupta R: Management issues in the metabolic 
syndrome.  J Assoc Physicians India 2006, 54:797-810.
2. Klein R, Klein BE, Cornoni J, Maready J, Cassel JC, Tyroler HA: Serum uric 
acid, Georgia.  Arch Intern Med 1973, 132:401-410.
3. Bengtsson C, Lapidus L, Stendahal C, Waldenstrom J: 1988. 
Hyperuricemia and risk of cardiovascular disease and overall death.  
Acta Med Scand 2002, 224:549-555.
4. Nakagawa T, Cirillo P, Sato W, Gersch M, Sautin Y, Roncal C: The 
conundrum of hyperuricemia, metabolic syndrome, and renal disease.  
Intern Emerg Med 2008, 3(4):313-318.
5. Cai Z, Xu X, Wu X, Zhou C, Li D: Hyperuricemia and the metabolic 
syndrome.  Asia Pac J Clin Nutr 2009, 18(1):81-87.
6. Chen LY, Zhu WH, Chen ZW, Di HL, Ren JJ: Relationship between 
hyperuricaemia and metabolic syndrome.  J Zhejiang Univ Sci B 2007, 
8(8):593-598.
7. Tuomilehto J, Wolf E, Taylor R, Ram P, King H: Plasma uric acid level and 
its association with diabetes mellitus and some biologic parameters in 
a biracial population of Fiji.  American Journal of Epidemiology 1988, 
127(2):321-336.
8. Reimann M, Schutte A, Malan L, Huisman H, Malan N: Hyperuricaemia is 
an independent factor for the metabolic syndrome in a sub-Saharan 
African population: A factor analysis.  Atherosclerosis 2008, 
197(2):638-645.
9. Palmer IM, Schutte AE, Huisman HW, Van Rooyen JM, Schutte R, Malan L: A 
comparison of uric acid levels in black Africans vs Caucasian women 
from South Afric: The POWIRS Study.  Ethnicity and disease 2007, 
17:676-670.
10. Abell LL, Levy BB, Brodie BB, Kendall FE: Simplified methods for the 
estimation of the total cholesterol in serum and demonstration of 
specificity.  J Biol Chem 1952, 195:357-366.
11. Lopez-Virella ML: Cholesterol determination in high-density 
lipoproteins separated by three different methods.  Clin Chem 1977, 
23:882-890.
12. Bucolo G, David H: Quantitative determination of serum triglycerides by 
the use of enzymes.  Clin Chem 1973, 19:476-582.
13. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration 
of low density lipoprotein cholesterol in plasma, without use of the 
preparative ultra centrifuge.  Clin Chem 1972, 18:499-502.
14. Cantrill JA: Diabetes Mellitus.  In Clinical Pharmacy and Therapeutics 2nd 
edition. Edited by: Walker R, Edwards C. Churchill Livingstone, London; 
1999:633-652. 
15. Alberti KG, Eckel RH, Grundy SM, Zimmet , Paul Z, Cleeman , James I, 
Donato Karen: Harmonizing the metabolic syndrome. A joint interim 
statement of the International Diabetes Federation Task Force on 
Epidemiology and Prevention.  In Circulation Volume 120. National Heart, 
Lung, and Blood Institute; American Heart Association; World Heart 
Federation; International Atherosclerosis Society; and International 
Association for the Study of Obesity; 2009:1640-1645. 
16. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN: Uric acid and the 
development of the metabolic syndrome in women and men.  
Metabolism 2008, 57(6):845-852.
17. Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp 
MF: Endogenous urate production augments plasma antioxidant 
capacity in healthy lowland subjects exposed to high altitude".  Chest 
2005, 131(5):1473-1478.
18. Nakagawa T, Hu H, Zharikov S: "A causal role for uric acid in fructose-
induced metabolic syndrome".  American Journal of Renal Physiology 
2006, 290(3):625-631.
19. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M: "Uric acid metabolism 
and tubular sodium handling. Results from a population-based study".  
JAMA 1993, 270(3):354-359.
20. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: "High 
serum uric acid as a novel risk factor for type 2 diabetes".  Diabetes Care 
2008, 31(2):361-362.
21. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F: 
Relationship of uric acid concentration to cardiovascular risk factors in 
young men. Role of obesity and central fat distribution.  Int J Obes Relat 
Metab Disord 1996, 20:975-380.
22. Lehto S, Niskanem L, Ronnemaa T, Laakso M: Serum uric acid is a strong 
predictor of stroke in patients with non-insulin dependent diabetes 
mellitus.  Stroke 1998, 29:635-639.
23. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F: 
Prevalence of hyperuricaemia and relation of serum uric acid in a 
developing country.  BMC Public Health 2004, 4:9.
24. Wingrove CS, Walton C, Stevenson JC: The effect of menopause on 
serum uric acid levels in non-obese healthy women.  Metabolism, 
clinical and experimental 1998, 47:435-438.
25. Lu Z, Dong B, Wu H, Chen T, Zhang Y, Xiao H: Serum uric acid level in 
primary hypertension among Chinese Nonagenarians/Centenarians.  J 
Hum Hypertens 2008, 23(2):113-121.
26. Kuzuya M: Effect of aging on serum uric acid levels: longitudinal 
changes in a large Japanese population group.  Journal of Gerontology 
2002, 57:660-664.
27. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH: 
Hyperuricemia in primary and renal hypertension.  N Engl J Med 1966, 
275:457-464.
28. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R: Serum uric 
acid and hypertension: the Olivetti heart study.  J Human Hypertens 
1994, 8:677-681.
29. Lu ZS, Lu ZH, Lu H, Yan SG, Wang JA, Li L, You W: Association between 
hyperuricemia and hypertension in a Chinese population at a high risk 
of hypertension.  Blood Press 2009, 8:1-5.
30. Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the 
metabolic syndrome: mechanisms mediating risk for metabolic and 
cardiovascular disease.  Curr Opin Lipidol 2007, 18(3):263-270.
31. Lin J, Chiou W, Chang H, Liu F, Weng H: Serum uric acid and leptin levels 
in metabolic syndrome: a quandary over the role of uric acid.  
Metabolism 2009, 56:751-756.
32. Hollister LE, Overall JE, Snow HL: Relationship of Obesity to Serum 
Triglyceride, Cholesterol, and Uric Acid, and to Plasma-Glucose Levels.  
American Journal of Clinical Nutrition 1967, 20:777-782.
33. Yamanaka H: Alcohol ingestion and hyperuricaemia.  Nippon Rinsho 
1996, 54(12):3369-3379.
34. Nakanishi N, Tatara K, Nakamura K, Suzuki K: Risk factors for the incidence 
of hyperuricaemia: a 6-year longitudinal study of middle-aged 
Japanese men.  International journal of epidemiology 1999, 28:888-893.
doi: 10.1186/1758-5996-2-24
Cite this article as: Ogbera and Azenabor, Hyperuricaemia and the meta-
bolic syndrome in type 2 DM Diabetology & Metabolic Syndrome 2010, 2:24
Received: 12 January 2010 Accepted: 20 April 2010 
Published: 20 April 2010
This article is available from: http://www.dmsjournal.com/content/2/1/24 © 2010 Ogbera and Azenabor; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Diabetology & Metabolic Syndrome 2010, 2:24